ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01347866
Recruitment Status : Terminated (Refer to Detailed Description for documentaion of Termination Statement.)
First Posted : May 4, 2011
Last Update Posted : January 14, 2016
Sponsor:
Information provided by (Responsible Party):
Pfizer

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Terminated
  Actual Primary Completion Date : December 2015
  Actual Study Completion Date : December 2015

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 November 15, 2016
January 12, 2017
2 February 13, 2017
March 31, 2017
3 May 30, 2017
January 23, 2018
4 February 13, 2018